简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2018-08-10 09:53 Merz Creates Americas Region, Expands Bob Rhatigan’s Leadership Role
2018-08-07 12:03 Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers
2018-08-06 15:40 Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Announce New Partnership to Develop First-in-Class Gene Therapy for Cystic Fibrosis
2018-08-03 17:53 Graminex® LLC successfully challenges Serelys’ patents for use of pollen extracts in treating women's PMS and menopausal symptoms
2018-08-02 17:53 Boehringer Ingelheim launches the initiative In Reach Africa to address key healthcare infrastructure and access priorities across Africa
2018-08-02 10:02 Clinical Innovations Accelerates Global Growth Strategy with Establishment of CI Medical Instruments in China
2018-08-02 09:34 Clover Biopharmaceuticals Initiates Phase I Study of Etanercept Biosimilar Candidate SCB-808 in China
2018-08-01 17:55 Takeda Reports First Quarter FY2018 Results
2018-07-30 13:46 HEX into Emerging Medical Blockchain Market
2018-07-30 13:44 TEAM ASTON Participates Blockchain World Conference Hybrid Summit 2018
2018-07-27 14:54 Starr Insurance Companies Appoints Santiago Mora as Head of International Accident & Health
2018-07-27 14:25 akeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve
2018-07-25 15:57 Banyan Biomarkers Announces Publication of ALERT-TBI Clinical Study Results in The Lancet Neurology
2018-07-24 10:00 FDA Clears First Nanotechnology Peek Devices for Spinal Intervertebral Fusion
2018-07-23 19:07 Ferring’s Heat-Stable Carbetocin Could Save Thousands of Women’s Lives by Preventing Excessive Bleeding after Childbirth
2018-07-20 13:05 Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease
2018-07-20 09:16 Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its primary endpoint
2018-07-19 13:59 22nd Century Announces the Immediate Feasibility of the FDA’s Nicotine Reduction Plan
2018-07-19 13:51 New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
2018-07-17 11:24 New Study Investigates the Utility of Masimo PVi® as Part of Goal-Directed Fluid Management in Patients Undergoing Colorectal Surgery

Business Wire Weibo

Press Releases

Latest Releases